Indication example

{
  "resourceType" : "ClinicalUseDefinition",
  "id" : "example-indication",
  "text" : {
    "status" : "extensions",
    "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p><b>Generated Narrative: ClinicalUseDefinition</b><a name=\"example-indication\"> </a></p><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\">Resource ClinicalUseDefinition &quot;example-indication&quot; </p></div><p><b>StructureDefinition Work Group</b>: brr</p><p><b>type</b>: indication</p><p><b>subject</b>: <a href=\"medicinalproductdefinition-example.html\">MedicinalProductDefinition/example</a></p><blockquote><p><b>indication</b></p><h3>DiseaseSymptomProcedures</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Concept</b></td></tr><tr><td style=\"display: none\">*</td><td>Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery. Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age ≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥ II). Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (indicationasdisease-symptom-procedure#Pulmonary-embolism-and-thrombosis-example-code)</span></td></tr></table><h3>DiseaseStatuses</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Concept</b></td></tr><tr><td style=\"display: none\">*</td><td>Recurrent <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (diseasestatus#Recurrent)</span></td></tr></table><h3>IntendedEffects</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Concept</b></td></tr><tr><td style=\"display: none\">*</td><td>PRYLX <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (intendedeffect#PRYLX)</span></td></tr></table></blockquote><p><b>population</b>: <a name=\"group\"> </a></p><blockquote><p/><p><a name=\"group\"> </a></p><p><b>type</b>: person</p><p><b>membership</b>: definitional</p><h3>Characteristics</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Code</b></td><td><b>Value[x]</b></td><td><b>Exclude</b></td></tr><tr><td style=\"display: none\">*</td><td>age-range <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (characteristic#age-range)</span></td><td>18-? a</td><td>false</td></tr></table></blockquote></div>"
  },
  "contained" : [{
    "resourceType" : "Group",
    "id" : "group",
    "type" : "person",
    "membership" : "definitional",
    "characteristic" : [{
      "code" : {
        "coding" : [{
          "system" : "http://ema.europa.eu/example/characteristic",
          "code" : "age-range"
        }]
      },
      "valueRange" : {
        "low" : {
          "value" : 18,
          "unit" : "a"
        }
      },
      "exclude" : false
    }]
  }],
  "extension" : [{
    "url" : "http://hl7.org/fhir/StructureDefinition/structuredefinition-wg",
    "valueCode" : "brr"
  }],
  "type" : "indication",
  "subject" : [{
    "reference" : "MedicinalProductDefinition/example"
  }],
  "indication" : {
    "diseaseSymptomProcedure" : {
      "concept" : {
        "coding" : [{
          "system" : "http://ema.europa.eu/example/indicationasdisease-symptom-procedure",
          "code" : "Pulmonary-embolism-and-thrombosis-example-code"
        }],
        "text" : "Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery. Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age ≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥ II). Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults."
      }
    },
    "diseaseStatus" : {
      "concept" : {
        "coding" : [{
          "system" : "http://ema.europa.eu/example/diseasestatus",
          "code" : "Recurrent"
        }]
      }
    },
    "intendedEffect" : {
      "concept" : {
        "coding" : [{
          "system" : "http://ema.europa.eu/example/intendedeffect",
          "code" : "PRYLX"
        }]
      }
    }
  },
  "population" : [{
    "reference" : "#group"
  }]
}